EC, Risk proportionate approaches in clinical trials

This 14‑page recommendations document, developed by the European Commission expert group on clinical trials, explains how to implement risk proportionate approaches under Regulation (EU) No 536/2014 for clinical trials on medicinal products for human use. It sets out how a structured risk assessment should inform trial design and conduct, so that procedures are adapted to the actual risks for participants, trial integrity and data reliability instead of following a uniform “one size fits all” model. 

• Clarifies the definition and conditions for low‑intervention clinical trials and links them to Organisation for Economic Co‑operation and Development categories A and B(1), with examples of minimal additional burden versus normal clinical practice.
• Describes risk‑based quality management steps (risk identification, evaluation, control, communication, review and reporting) and how these support proportionate decisions on monitoring, safety reporting, investigational medicinal product traceability and Trial Master File content, mapped to relevant Regulation articles.
• Applies to commercial and non‑commercial sponsors across all phases, and is especially useful for academic and investigator‑initiated studies that need to justify streamlined monitoring, targeted adverse event recording and pragmatic documentation while remaining compliant with Good Clinical Practice and regulatory requirements.